The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
December 26, 2016 - 5 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- The COVID-19 pandemic has driven RNA therapeutics into the mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
These are our 10 Most Read Biotech Articles of 2016
From the hottest research areas to the most popular city for biotech, which biotech articles have…
December 20, 2016 - 4 minutes
Up, up and away! CureVac’s money pile now Totals €325M
CureVac has raised an additional €27M ($29.5M) that will help the company keep on its…
November 9, 2016 - 3 minutes
German Biotech allies with Genentech in battle for Cancer Vaccine
BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for…
September 21, 2016 - 3 minutes
mRNA Money-magnet increases its Pile of Cash to over €1.3Bn
Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership…
August 12, 2016 - 2 minutes
AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease
The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is…
July 27, 2016 - 3 minutes
First All-Cancer mRNA Vaccine that Works Published in Nature
Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all…
June 2, 2016 - 3 minutes
German mRNA specialist moves into Animal Health in collaboration with Bayer
BioNTech is joining its mRNA technology with Bayer's expertise in veterinary applications in a new…
May 11, 2016 - 2 minutes
Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?
What if we could send the body an instruction to produce its own drug? That’s…
January 5, 2016 - 7 minutes
What are Money-Magnet Moderna’s future plans? French Founding CEO explains here
Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel,…
November 16, 2015 - 1 minute
What happened this week? mRNA Therapies, TCR & Algae Beer
Monday: Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer Tuesday: What the FUGT? We tried…
November 14, 2015 - 1 minute
Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market
I am still at the mRNA Convention in Berlin...and was invited for a second interview…
November 12, 2015 - 1 minute
